Glaucoma Medication Market Developments by 2031
Glaucoma is a slowly growing eye disorder that mainly occurs in geriatric population. the patients with growing glaucoma are high in number so that many government hospitals have opened a separate division for the treatment glaucoma patients. Surgery is the only option for the cure of glaucoma after therapeutic medication. There are various risks with the opthal surgeries in glaucoma due to covid 19 so that therapeutic medication is the primary for the treatment.
MARKET SCOPE
The "Global Glaucoma Medication Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Glaucoma Medication market with detailed market segmentation by drug class and distribution channel. The report provides key statistics on the market status of the leading Glaucoma Medication market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- Based on type the market is segmented as, vaccines and therapeutics drug.
- Based on transmission the market is segmented as, direct contact and indirect contact.
- Based on infection type the market is segmented as, bacterial infection, fungal infection, and viral infection.
MARKET DYNAMICS
Drivers:
- Rising prevalence of Glaucoma in adults and geriatric patients.
- Increasing severity of ophthalmic disorders.
- Extensive R&D efforts by pharmaceutical companies to develop novel therapies for glaucoma is expected to fuel the market growth.
Restraints:
- Whereas, high cost of treatment for glaucoma is expected to restrain market growth during the forecast period.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South and Central America. The Glaucoma Medication market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South and Central America after evaluating political, economic, social and technological factors affecting the Glaucoma Medication market in these regions.
IMPACT OF COVID-19 ON GLAUCOMA MEDICATION MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South and Central America. The Glaucoma Medication market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South and Central America after evaluating political, economic, social and technological factors affecting the Glaucoma Medication market in these regions.
IMPACT OF COVID-19 ON GLAUCOMA MEDICATION MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
MARKET PLAYERS
The report covers key developments in the Glaucoma Medication market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from Glaucoma Medication market are anticipated to lucrative growth opportunities in the future with the rising demand for Glaucoma Medication in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Glaucoma Medication market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- Merck and Co., Inc.
- Novartis
- Allergan
- AERIE PHARMACEUTICALS, INC.
- Bausch and Lomb Incorporated
- Pfizer
- Santen Pharmaceutical.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Glaucoma Medication Market - By Drug Class
1.3.2 Glaucoma Medication Market - By Disease
1.3.3 Glaucoma Medication Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. GLAUCOMA MEDICATION MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS
5. GLAUCOMA MEDICATION MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. GLAUCOMA MEDICATION MARKET - GLOBAL MARKET ANALYSIS
6.1. GLAUCOMA MEDICATION - GLOBAL MARKET OVERVIEW
6.2. GLAUCOMA MEDICATION - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. GLAUCOMA MEDICATION MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. BETA BLOCKER
7.3.1. Overview
7.3.2. Beta Blocker Market Forecast and Analysis
7.4. PROSTAGLANDIN ANALOG
7.4.1. Overview
7.4.2. Prostaglandin Analog Market Forecast and Analysis
7.5. CARBONIC ANHYDRASE INHIBITOR
7.5.1. Overview
7.5.2. Carbonic Anhydrase Inhibitor Market Forecast and Analysis
7.6. ALPHA ADRENERGIC AGONISTS
7.6.1. Overview
7.6.2. Alpha Adrenergic Agonists Market Forecast and Analysis
7.7. COMBINATION DRUGS
7.7.1. Overview
7.7.2. Combination Drugs Market Forecast and Analysis
8. GLAUCOMA MEDICATION MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE
8.1. OVERVIEW
8.2. DISEASE MARKET FORECASTS AND ANALYSIS
8.3. CLOSE ANGLE GLAUCOMA
8.3.1. Overview
8.3.2. Close Angle Glaucoma Market Forecast and Analysis
8.4. OPEN ANGLE GLAUCOMA
8.4.1. Overview
8.4.2. Open Angle Glaucoma Market Forecast and Analysis
9. GLAUCOMA MEDICATION MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Glaucoma Medication Market Overview
9.1.2 North America Glaucoma Medication Market Forecasts and Analysis
9.1.3 North America Glaucoma Medication Market Forecasts and Analysis - By Drug Class
9.1.4 North America Glaucoma Medication Market Forecasts and Analysis - By Disease
9.1.5 North America Glaucoma Medication Market Forecasts and Analysis - By Countries
9.1.5.1 United States Glaucoma Medication Market
9.1.5.1.1 United States Glaucoma Medication Market by Drug Class
9.1.5.1.2 United States Glaucoma Medication Market by Disease
9.1.5.2 Canada Glaucoma Medication Market
9.1.5.2.1 Canada Glaucoma Medication Market by Drug Class
9.1.5.2.2 Canada Glaucoma Medication Market by Disease
9.1.5.3 Mexico Glaucoma Medication Market
9.1.5.3.1 Mexico Glaucoma Medication Market by Drug Class
9.1.5.3.2 Mexico Glaucoma Medication Market by Disease
9.2. EUROPE
9.2.1 Europe Glaucoma Medication Market Overview
9.2.2 Europe Glaucoma Medication Market Forecasts and Analysis
9.2.3 Europe Glaucoma Medication Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Glaucoma Medication Market Forecasts and Analysis - By Disease
9.2.5 Europe Glaucoma Medication Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Glaucoma Medication Market
9.2.5.1.1 Germany Glaucoma Medication Market by Drug Class
9.2.5.1.2 Germany Glaucoma Medication Market by Disease
9.2.5.2 France Glaucoma Medication Market
9.2.5.2.1 France Glaucoma Medication Market by Drug Class
9.2.5.2.2 France Glaucoma Medication Market by Disease
9.2.5.3 Italy Glaucoma Medication Market
9.2.5.3.1 Italy Glaucoma Medication Market by Drug Class
9.2.5.3.2 Italy Glaucoma Medication Market by Disease
9.2.5.4 Spain Glaucoma Medication Market
9.2.5.4.1 Spain Glaucoma Medication Market by Drug Class
9.2.5.4.2 Spain Glaucoma Medication Market by Disease
9.2.5.5 United Kingdom Glaucoma Medication Market
9.2.5.5.1 United Kingdom Glaucoma Medication Market by Drug Class
9.2.5.5.2 United Kingdom Glaucoma Medication Market by Disease
9.2.5.6 Rest of Europe Glaucoma Medication Market
9.2.5.6.1 Rest of Europe Glaucoma Medication Market by Drug Class
9.2.5.6.2 Rest of Europe Glaucoma Medication Market by Disease
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Glaucoma Medication Market Overview
9.3.2 Asia-Pacific Glaucoma Medication Market Forecasts and Analysis
9.3.3 Asia-Pacific Glaucoma Medication Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Glaucoma Medication Market Forecasts and Analysis - By Disease
9.3.5 Asia-Pacific Glaucoma Medication Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Glaucoma Medication Market
9.3.5.1.1 Australia Glaucoma Medication Market by Drug Class
9.3.5.1.2 Australia Glaucoma Medication Market by Disease
9.3.5.2 China Glaucoma Medication Market
9.3.5.2.1 China Glaucoma Medication Market by Drug Class
9.3.5.2.2 China Glaucoma Medication Market by Disease
9.3.5.3 India Glaucoma Medication Market
9.3.5.3.1 India Glaucoma Medication Market by Drug Class
9.3.5.3.2 India Glaucoma Medication Market by Disease
9.3.5.4 Japan Glaucoma Medication Market
9.3.5.4.1 Japan Glaucoma Medication Market by Drug Class
9.3.5.4.2 Japan Glaucoma Medication Market by Disease
9.3.5.5 South Korea Glaucoma Medication Market
9.3.5.5.1 South Korea Glaucoma Medication Market by Drug Class
9.3.5.5.2 South Korea Glaucoma Medication Market by Disease
9.3.5.6 Rest of Asia-Pacific Glaucoma Medication Market
9.3.5.6.1 Rest of Asia-Pacific Glaucoma Medication Market by Drug Class
9.3.5.6.2 Rest of Asia-Pacific Glaucoma Medication Market by Disease
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Glaucoma Medication Market Overview
9.4.2 Middle East and Africa Glaucoma Medication Market Forecasts and Analysis
9.4.3 Middle East and Africa Glaucoma Medication Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Glaucoma Medication Market Forecasts and Analysis - By Disease
9.4.5 Middle East and Africa Glaucoma Medication Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Glaucoma Medication Market
9.4.5.1.1 South Africa Glaucoma Medication Market by Drug Class
9.4.5.1.2 South Africa Glaucoma Medication Market by Disease
9.4.5.2 Saudi Arabia Glaucoma Medication Market
9.4.5.2.1 Saudi Arabia Glaucoma Medication Market by Drug Class
9.4.5.2.2 Saudi Arabia Glaucoma Medication Market by Disease
9.4.5.3 U.A.E Glaucoma Medication Market
9.4.5.3.1 U.A.E Glaucoma Medication Market by Drug Class
9.4.5.3.2 U.A.E Glaucoma Medication Market by Disease
9.4.5.4 Rest of Middle East and Africa Glaucoma Medication Market
9.4.5.4.1 Rest of Middle East and Africa Glaucoma Medication Market by Drug Class
9.4.5.4.2 Rest of Middle East and Africa Glaucoma Medication Market by Disease
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Glaucoma Medication Market Overview
9.5.2 South and Central America Glaucoma Medication Market Forecasts and Analysis
9.5.3 South and Central America Glaucoma Medication Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Glaucoma Medication Market Forecasts and Analysis - By Disease
9.5.5 South and Central America Glaucoma Medication Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Glaucoma Medication Market
9.5.5.1.1 Brazil Glaucoma Medication Market by Drug Class
9.5.5.1.2 Brazil Glaucoma Medication Market by Disease
9.5.5.2 Rest of South and Central America Glaucoma Medication Market
9.5.5.2.1 Rest of South and Central America Glaucoma Medication Market by Drug Class
9.5.5.2.2 Rest of South and Central America Glaucoma Medication Market by Disease
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. GLAUCOMA MEDICATION MARKET, KEY COMPANY PROFILES
11.1. MERCK AND CO., INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. NOVARTIS
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. ALLERGAN
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. AERIE PHARMACEUTICALS, INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. BAUSCH AND LOMB INCORPORATED
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. PFIZER
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. SANTEN PHARMACEUTICAL.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1.Merck and Co., Inc.
2.Novartis
3.Allergan
4.AERIE PHARMACEUTICALS, INC.
5.Bausch and Lomb Incorporated
6.Pfizer
7.Santen Pharmaceutical.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For